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As gastrin may play a role in the pathophysiology of gastrointestinal (GI) malignancies, the elucidation of the mechanisms governing
gastrin-induced proliferation has recently gained considerable interest. Several studies have reported that a large percentage of
colorectal tumours overexpress or stabilise the b-catenin oncoprotein. We thus sought to determine whether gastrin might regulate
b-catenin expression in colorectal tumour cells. Amidated gastrin-17 (G-17), one of the major circulating forms of gastrin, not only
enhanced b-catenin protein expression, but also one of its target genes, cyclin D1. Furthermore, activation of b-catenin-dependent
transcription by gastrin was confirmed by an increase in LEF-1 reporter activity, as well as enhanced cyclin D1 promoter activity.
Finally, G-17 prolonged the t1/2 of b-catenin protein, demonstrating that gastrin appears to exert its mitogenic effects on colorectal
tumour cells, at least in part, by stabilising b-catenin.
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Gastrin was originally described as a gastrointestinal (GI)
regulatory peptide whose principal function was to stimulate
postprandial gastric acid secretion. However, in addition to its
recognised role in the physiological regulation of acid secretion,
another biological property attributed to gastrin is its trophic
effects. A prospective study by Thorburn et al (1998) suggested
that hypergastrinemia is associated with an increased risk for
colorectal cancer (CRC), and numerous studies have demonstrated
that gastrin stimulates the growth of malignant colorectal
adenocarcinomas (Wang et al, 1996; Malecka-Panas et al, 1997;
Baldwin & Shulkes, 1998; Nakata et al, 1998; Koh et al, 1999;
Stepan et al, 1999; Smith & Watson, 2000). Transgenic mice
overexpressing progastrin and glycine-extended gastrin demon-
strate enhanced colonic proliferation (Wang et al, 1996; Koh et al,
1999), and conversely, gastrin-deficient mice manifest decreased
colonic proliferation (Koh et al, 1997). Repression of the gastrin
gene in human colon cancer cells by antisense gastrin RNA yields a
significant growth inhibition of these cells, suggesting that gastrin
expression may be required for colon tumour progression (Singh
et al, 1996). Although these studies all suggest a role for gastrin in
the pathogenesis of CRC, little is known regarding the factors and
mechanisms involved in mediating the trophic properties of this
important peptide.
Overwhelming evidence derived from studies involving primary
colon tumours of both hereditary and sporadic origin has
implicated aberrations of the adenomatous polyposis coli (APC)
tumour suppressor gene and b-catenin oncogene in the pathogen-
esis of CRC (Kinzler & Vogelstein, 1996; Mirabelli-Primdahl et al,
1999; Miyaki et al, 1999; Samowitz et al, 1999). Although multiple
mechanisms may induce the neoplastic growth of colorectal
tumours, b-catenin appears to play a pivotal role in this process.
Under normal conditions, b-catenin degradation ensures tightly
regulated cytoplasmic levels of this protein. Adenomatous poly-
posis coli appears to regulate the degradation of b-catenin protein
by recruiting b-catenin into the negative regulatory complex for
phosphorylation by glycogen synthase kinase 3b (GSK3b) in the N-
terminus (Dominguez et al, 1995; Yost et al, 1996; Korinek et al,
1997) and subsequent proteasomal degradation (Aberle et al,
1997). Intricate interactions among other b-catenin binding
partners also serve to facilitate the degradation of b-catenin to
maintain a delicate balance (Ikeda et al, 1998; Kishida et al, 1998;
Li et al, 1999; Farr et al, 2000). In contrast to the proteasomal
degradation of b-catenin, which normally serves as a negative
regulator of tumorigenesis, a positive regulator of b-catenin and
tumorigenesis has also been identified. Protein kinase CK2
(formerly known as casein kinase 2), a serine/threonine kinase
that is overexpressed in many malignancies, has been shown to
phosphorylate b-catenin in the midportion of the protein and
enhance its stability (Song et al, 2000, 2003a).
When b-catenin escapes its negative regulatory mechanisms, it
translocates into the nucleus and functions as a critical transcrip-
tional coactivator of the T-cell factor/lymphocyte enhancer
binding factor (TCF/LEF), which activates oncogenes, such as c-
myc (He et al, 1998) and cyclin D1 (Shtutman et al, 1999). Thus,
activating mutations or stabilisation of b-catenin represent a
critical process in the growth of the human CRC. Many b-catenin
target genes have also been demonstrated as important factors in
the pathogenesis of CRC. In particular, cyclin D1 was upregulated
in human colorectal tumours and was associated with altered
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sb-catenin expression (Wang et al, 2002). Moreover, increased
levels of both b-catenin and cyclin D1 were found in a clinical
analysis of tissue samples obtained from CRC patients (Utsuno-
miya et al, 2001) and in the colonic tissue extracts of mice when
hyperproliferation/hyperplasia was induced (Sellin et al, 2001).
Interestingly, an association between gastrin and b-catenin
was not made until Koh et al (2000) identified gastrin as a
downstream target gene of b-catenin/TCF transcription. Because
these factors are important contributors to CRC growth, we sought
to determine whether additional relationships might exist
between gastrin and b-catenin. We have previously demonstrated
the trophic properties of gastrin in mouse colorectal tumour cells
(MC-26), in which the peptide caused a significant incorporation
of [
3H]thymidine at 24 and 48h (Yao et al, 2002). Furthermore,
when MC-26 cells were injected subcutaneously into BALB/C mice
and treated with amidated gastrin-17 (G-17) by continuous
infusion, the weight and volume of resulting tumour tissues
were significantly greater than in untreated controls (Yao et al,
2002).
In the present study, to determine whether the tropic properties
of G-17 might involve modulation of b-catenin, MC-26 cells were
treated with various concentrations of G-17, and various aspects of
b-catenin expression were examined. We observed that G-17 not
only enhanced the expression of total cellular b-catenin, but also
increased nuclear b-catenin accumulation and b-catenin-depen-
dent LEF-1 activity. Furthermore, cyclin D1 protein levels and
promoter activity were enhanced by G-17. Finally, treatment with
G-17 prolonged the half-life of b-catenin protein, suggesting that
one of the major mechanisms by which G-17 might induce its
trophic effects is through stabilisation of the multifunctional
ongogenic b-catenin protein. The results of our studies are
consistent with the presence of a vicious cycle between gastrin
and b-catenin that would favour an environment for uncontrolled,
aggressive CRC growth.
MATERIALS AND METHODS
Cell culture and treatments
We utilised MC-26 mouse CRC cells, which were maintained in
Dulbecco’s modified Eagle’s Medium (DMEM; Gibco Laboratories,
Grand Island, NY, USA), supplemented with 10% fetal bovine
serum (Gibco) and 1% penicillin/streptomycin. Amidated G-17
(Peninsula/Bachem, Belmont, CA, USA) was added to the culture
medium (20–100nM) for 2–4h, and 1mM of the gastrin-specific
receptor antagonist L365,260 (kindly provided by Dr L Iverson,
Oxford, UK) was used in conjunction with G-17 in the indicated
experiments. Cycloheximide, a de novo protein synthesis inhibitor,
was used at a final concentration of 10mgml
 1, either alone or in
combination with 20 or 50nM G-17 for the indicated times (0, 3, 6,
and 24h).
Northern analysis
Total RNA was extracted using the Qiagen RNeasy kit (Qiagen Inc.,
Valencia, CA, USA) following the manufacturer’s instructions.
Each RNA sample (10mg) was loaded onto a formaldehyde-
containing agarose gel and transferred via capillary action
overnight onto a Hybond-N nylon membrane (Amersham
Pharmacia, Piscataway, NJ, USA) in 10 SSC buffer. Transferred
membrane was crosslinked and prehybridised prior to the
addition of the labelled probe. Approximately 1kb fragment of
b-catenin cDNA and 3.2kb fragment of actin cDNA were
excised and used as probes. Both of the probes were labelled
with [
32P]dCTP for 30min, purified with Quick Spin
sephadex G-25 columns (Roche, Basel, Switzerland), boiled, and
incubated with prehybridised membrane overnight at 651C.
Labelled membranes were washed four times, twice in 2 SSC/
0.1% SDS and twice in 0.2 SSC/0.1% SDS, before exposing
to a film. The membrane was briefly stripped with boiling 0.1%
SDS and washed 3  with 2 SSC before addition of another
probe.
Western analysis
Total protein was extracted, as previously described (Song et al,
2000, 2003a). For nuclear protein extraction, a protocol described
by Dignam et al (1983) was followed. Briefly, cells were washed
twice in 1  phosphate-buffered saline (PBS) and scraped in the
presence of 200mM EDTA in PBS. Through Dounce homogenation
and differential centrifugation, nuclear proteins were separated
from cytoplasmic fractions in the presence of protease inhibitors.
Protein quantification was performed using the BCA protein
assay.
Western blotting analyses were performed, as previously
described (Song et al, 2000, 2003a), using antibodies against b-
catenin (Transduction Laboratories, Lexington, KY, USA) and
cyclin D1 (Pharmingen, Chicago, IL, USA). Ponceau S (Sigma, St
Louis, MO, USA) staining and immunoblots with either a
monoclonal b-actin antibody (Sigma) for whole-cell lysates or
polyclonal Sp1 antibody (Santa Cruz, Santa Cruz, CA, USA) for
nuclear extracts were used to confirm equal loading of Western
blot membranes.
Reporter assays
MC-26 cells (1–2 10
5) were plated 1 day prior to transfection.
For transient transfection experiments, subconfluent cells
were incubated with DNA and FUGENE-6 liposome reagent
(Boehringer Mannheim, Mannheim, Germany) according to the
manufacturer’s instructions. Both LEF-1 and cyclin D1 (minimal
and full-length cyclin D1 promoter-luciferase constructs; Albanese
et al, 2003) experiments utilised the FUGENE-6 transfection
reagent to deliver the target plasmids. In addition, renilla
was cotransfected with the firefly reporter plasmids to normalise
for transfection efficiency. Total DNA was balanced with the
addition of empty vector when multiple plasmids were used. At
24h after the transfection, the cells were incubated with 20
and 50nM G-17 for 4h, harvested, and assayed for firefly luciferase
reporter and for renilla activity. Briefly, 10ml of protein extract
was first assayed with 50ml of firefly luciferase substrate
(Promega, Madison, WI, USA) in a luminometer for 10s.
Subsequently, in the same tube, 50ml renilla substrate (Promega)
were added and measured. Samples were assayed in duplicate,
and the luciferase counts were normalised to renilla measure-
ments.
In vitro kinase assay
Equal amounts of protein extracted from MC-26 cells (10mg) were
assayed for CK2 kinase activity, as previously described (Song et al,
2000, 2003a). Briefly, each sample was assayed in duplicate with
and without CK2-specific synthetic peptide, RRREEETEEE (Pro-
mega), for 20min at 371C with 5mCi [g-
32P]ATP. Radioactive
counts were blotted onto p81 filter circles, washed 4  in 150mM
H3PO4, and analysed on an automated liquid scintillation counter.
Buffer controls with and without the substrate peptide (back-
ground control) were also measured and subtracted from the final
radioactive counts.
Statistical analysis
The two-way Student’s t-test was performed for paired compar-
isons. Statistical significance was assigned if Po0.05.
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Gastrin-17 enhances b-catenin protein levels in MC-26 cells
To determine the potential role of gastrin in modulating b-catenin,
mRNA and protein levels were measured by Northern and Western
blot hybridisations, respectively, in MC-26 cells that were
transiently treated with G-17. Although incubation of MC-26 cells
in the presence of G-17 did not alter the concentration of b-catenin
transcripts (Figure 1A), total protein level of b-catenin was
significantly enhanced by 20 and 50nM G-17 following both 2
and 4h of incubation (Figure 1B). Furthermore, coincubation with
L365,260, a gastrin receptor (CCK2) antagonist, attenuated the
upregulation of b-catenin by greater than 50%, suggesting that the
increase in b-catenin was specific (Figure 1C). An induction of b-
catenin was consistently detected, and the results were reproduced
on four separate occasions. Although the magnitude of the change
in total b-catenin protein varied within individual experiments, a
3–4-fold increase in total b-catenin protein levels was detected
when bands were quantified by densitometry and normalised to
b-actin levels (Figure 1D).
As mentioned above, nuclear accumulation of b-catenin
represents a key event in CRC progression. To examine whether
G-17 can enhance nuclear b-catenin in MC-26 cells, cells were
treated with G-17 for 4h and nuclear extracts were prepared. In all,
20 and 50nM G-17 induced approximately a two-fold increase in
nuclear b-catenin levels (Figure 1E), suggesting that G-17
promotes nuclear translocation of b-catenin. Expression of Sp1,
a ubiquitously expressed transcription factor, was used as a
loading control for nuclear extracts.
Gastrin-17 increases LEF-1-dependent transcriptional
activity
To examine whether the increase in nuclear b-catenin protein is
also associated with the activation of LEF-1, LEF-1-dependent
reporter assays were performed. The pGL3-LEF-1 luciferase
construct (kindly provided by Dr R Grosschedl, Munich, Germany)
contains eight repeats of the LEF binding site that is activated only
in the presence of an exogenous LEF-1 construct. The level of LEF-
1-dependent transcription is also dependent on nuclear b-catenin
levels, as b-catenin is a known coactivator for TCF/LEF transcrip-
tion factors. As we speculated that an increase in b-catenin protein
by G-17 might be functionally important for the transcriptional
activation of its target genes, LEF-1-dependent reporter assays
were performed in the absence and presence of G-17. We observed
that 20 and 50nM G-17 induced a concentration-dependent
increase in LEF-1-dependent transcriptional activity (Pp0.005)
(Figure 2). In addition, the effects of gastrin on cyclin D1, one of
the target genes of b-catenin-dependent transcription, were
analysed. In response to the inclusion of G-17 in the culture
medium, both cyclin D1 protein levels and promoter activity were
increased (Figure 3). Specifically, 50nM G-17 significantly en-
hanced the activity of the full-length cyclin D1 promoter ( 1745)
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Figure 1 (A) Gastrin does not affect b-catenin mRNA levels, as
demonstrated by Northern blot analysis. MC-26 cells were incubated for
4h in the presence of increasing concentrations of G-17 (10–100nM;
upper panel). 28S and 18S ribosomal RNAs are indicated on the left, and
actin was used as a loading control (lower panel). (B) Gastrin increases b-
catenin protein levels, as demonstrated by Western blot analysis.
Compared to untreated samples, 2 and 4h of treatment with 20 and
50nM G-17 caused a significant increase in b-catenin protein levels (upper
panel). b-Actin was used as a loading control (lower panel). (C) The
addition of 1mM L365,260, a gastrin-specific receptor antagonist, attenuated
b-catenin induction by G-17 (upper panel, lane 5), indicating that the
increase in b-catenin was gastrin-specific. (D) Average per cent change of
b-catenin when normalised to b-actin levels, as measured by densitometry,
of four independent experiments. Densitometry units were measured
within each individual experiment and compared to control values, which
were designated 100%, and per cent change in response to G-17 treatment
was calculated. Data represent mean per cent of control7s.e. (n¼4).
*Pp0.05; **Pp0.01. (E) G-17 (20 and 50nM) enhanced nuclear b-catenin
levels (upper panel). Sp1, a nuclear protein, was used as a loading control
(lower panel).
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swhen compared to either the empty or minimal promoter ( 66)
(Figure 3B, Pp0.01).
Gastrin-17 stabilises b-catenin protein by increasing its
half-life in MC-26 cells
Since we observed that G-17 did not change the number of b-
catenin transcripts but increased b-catenin protein levels, protein
stability of b-catenin was next examined. To determine this, MC-26
cells were incubated with cycloheximide, a de novo protein
synthesis inhibitor, either in the absence or presence of 20 and
50nM G-17. Because b-catenin is normally degraded by protea-
somes, the addition of cycloheximide would enable the pool of
translated cytoplasmic protein to be degraded at its natural rate.
Total protein was extracted at 0, 3, and 6h, and b-catenin protein
levels were measured by Western analysis. In the presence of
cycloheximide alone, nearly 50% of b-catenin was degraded by 3h
(Figure 4A and C). However, coincubation with either 20 or 50nM
G-17 stabilised b-catenin and prolonged its half-life. Even after 6h
of treatment, b-catenin protein levels were largely unchanged in
cells cultured in the presence of G-17 (Figure 4A). Specifically, the
half-life of b-catenin in the presence of 50nM G-17 was
approximately 24h, whereas nearly complete degradation of b-
catenin protein was detected with cycloheximide alone at 24h
(Figure 4B and C). An approximate three-fold difference in b-
catenin levels was detected between control conditions and
following incubation in the presence of 50nM G-17 at 24h,
suggesting that G-17 modulates b-catenin by stabilisation of the
protein (Figure 4C).
To delineate the mechanism by which gastrin might cause
stabilisation of b-catenin, we examined two known regulators of b-
catenin. Specifically, GSK3b, an upstream negative regulator of b-
catenin that promotes proteasomal degradation of b-catenin, and
protein kinase CK2, a positive regulator, were examined. No
consistent effect on GSK3b kinase activity could be demonstrated
in response to the incubation of MC-26 cells in media containing
various concentrations of G-17 (data not shown). In contrast, 20
and 50nM G-17 caused a marked increase in endogenous CK2
kinase activity (Figure 5A). Moreover, coincubation of 20nM G-17
with apigenin, a purportedly selective CK2 inhibitor, attenuated
total b-catenin protein levels compared to 20nM G-17 alone,
suggesting that G-17 may utilise CK2 to regulate b-catenin
(Figure 5B). However, the addition of apigenin to media contain-
ing increasing concentrations of G-17 did not abolish the
induction of b-catenin (Figure 5B).
DISCUSSION
Both gastrin and various components of the b-catenin-dependent
signaling pathway have been implicated in the pathogenesis of
CRC (Nusse, 2002). However, a functionally relevant association
between gastrin and b-catenin was not made until Koh et al (1997,
2000) demonstrated that gastrin-deficient APC (min
 /þ) mice
produced fewer polyps than APC (min
 /þ) mice overexpressing
gastrin. Furthermore, these investigators showed that b-catenin
enhanced gastrin promoter activity, thus identifying gastrin as one
of its numerous downstream targets. However, the possibility of a
positive feedback relationship between gastrin and b-catenin
expression has not been examined previously.
Utilising transplantable mouse CRC cells (MC-26) that express
functional gastrin receptors, we have previously demonstrated the
trophic properties of gastrin (Yao et al, 2002). We hypothesised
that one of the mechanisms by which gastrin might exert its
trophic properties may involve the multifunctional b-catenin
protein. We consistently observed that gastrin increases b-catenin
protein levels. However, despite our attempts to maintain
consistency, such as plating equal amounts of cells 1 day prior
to each individual experiment, we nevertheless did observe some
variability in the basal expression (untreated) of b-catenin during
the performance of different experiments. This variability may be
due in part to the role of b-catenin in cell–cell adhesion, which,
Figure 2 Gastrin-17 enhances LEF-1-dependent transcriptional activity.
The representative figure shows LEF-1-dependent transcriptional activity
(light units) normalised to renilla to control for transfection efficiency. Each
sample was transfected and assayed in duplicate. *Pp0.005.
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Figure 3 Gastrin-17 increases cyclin D1 protein and full-length
promoter activity. (A) In addition to an increase in b-catenin levels, cyclin
D1 protein levels were also enhanced by treatment with G-17 after 4h. b-
Actin was used as control for loading. (B) MC-26 cells transfected with
empty,  66CD1 (minimal cyclin D1 promoter), or  1745CD1 (full-length
cyclin D1 promoter) luciferase constructs for 24h were either left
untreated or treated with 50nM G-17 for an additional 4h. Renilla was
cotransfected to control for transfection efficiency, and cells were
examined for luciferase and renilla activity. While activity of the minimal
promoter ( 66CD1) was not altered, full-length promoter ( 1745CD1)
activity was markedly enhanced by 50nM G-17. Each sample was
transfected and assayed in duplicate. Values represent mean7s.e.
(n¼3). *Pp0.01.
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sdepending on cell density, may contribute to the variability in
basal b-catenin expression.
Further examination of MC-26 cells in the present study
suggests that gastrin prolongs the half-life of b-catenin by
increasing its stability. Thus, it appears that b-catenin enhances
gastrin expression, and conversely, b-catenin protein expression is
stabilised by gastrin, completing a vicious cycle that may
contribute to neoplastic cell survival and growth. Moreover, data
presented in this study provide further evidence for the complex
nature of the oncogenic process by suggesting that gastrin utilises
multiple pathways in regulating b-catenin. In the present study, we
observed that gastrin stimulated CK2 activity and that gastrin-
stimulated b-catenin expression was partially attenuated in the
presence of the CK2 selective inhibitor apigenin. Inhibition of CK2
activity did not abolish gastrin-mediated effects on b-catenin,
suggesting that gastrin signalling possesses both CK2-dependent
and -independent properties. It is plausible that this important
regulatory peptide controls b-catenin through multiple regulators,
as b-catenin itself is known to have numerous modulators
(Dominguez et al, 1995; Yost et al, 1996; Korinek et al, 1997;
Ikeda et al, 1998; Kishida et al, 1998; Li et al, 1999; Farr et al, 2000;
Song et al, 2000, 2003a).
The existence of a pathological vicious cycle (a positive feedback
loop) involving b-catenin, as we postulate, would serve to enhance
the survival and continued growth of CRC cells by selectively
upregulating various oncogenic factors. A recent study has
suggested the existence of another pathological vicious cycle
involving b-catenin in CRC. In addition to its effects on gastrin and
on the expression of other target genes, Hovanes et al (2001)
reported that LEF-1, one of the transcriptional partners of b-
catenin, is likewise a target gene of b-catenin/TCF-dependent
transcription.
The upregulation of b-catenin expression by gastrin was also
associated with the enhancement of the critical cell cycle regulator,
cyclin D1. Consistent with our current findings, we have previously
reported that gastrin enhanced cyclin D1 protein and cyclin D1
promoter activity in the human gastric adenocarcinoma cell line
AGS-B (Song et al, 2003b). However, in contrast to the present
study, we did not observe an increase in b-catenin protein
expression in AGS-B cells incubated in the presence of gastrin.
Several possibilities may explain these disparate results, including
interspecies variations. Another possibility is the fact that AGS-B
cells have been engineered to overexpress the gastrin receptor,
which could potentially favour a direct increase in cyclin D1 by
gastrin rather than utilising b-catenin as a mediator of transcrip-
tion. Furthermore, overexpression of the receptor may have
modulated other components that could affect b-catenin stability.
Despite our observation in the present study that both b-catenin
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Figure 4 Gastrin-17 stabilises b-catenin. Equal amounts of MC-26 cells
were treated with 10mgml
 1 cycloheximide (CHX) in the absence or
presence of 20 or 50nM G-17. (A) After 0, 3, and 6h of treatment and (B)
0 and 24h of treatment. In the presence of CHX only, b-catenin was
degraded by approximately 50% after only 3h. Coincubation of CHX with
either 20 or 50nM G-17 delayed the degradation of b-catenin. 50nM G-17
caused a 50% reduction of b-catenin protein level after 24h. b-Actin was
used as a loading control. (C) Quantification of Western blot analysis
examining b-catenin degradation. Values represent mean7s.e. (n¼3). —
Control; – – 50nM G-17.
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Figure 5 Gastrin-17 increases CK2 activity. (A) Endogenous protein
kinase CK2 activity was examined by an in vitro kinase assay employing the
measurement of [g-
32P]ATP incorporation into the CK2-specific substrate
peptide RRREEETEEE (þpeptide). In addition, in the same assay,
background and nonpeptide-specific kinase activity was measured in the
absence of the substrate ( peptide). Compared to untreated cells, 20 and
50nM G-17 enhanced CK2 activity in the presence of the CK2 substrate.
*Pp0.00003. (B) MC-26 cells were either treated for 5h with 80mM
apigenin alone or pretreated for 1h with 80mM apigenin followed by 4h of
co-incubation with various concentrations of G-17. Total protein levels of
b-catenin as well as b-actin loading control are shown. Treatment with
20nM G-17 alone (lane 7) caused more b-catenin accumulation than
coincubation of 20nM G-17 and apigenin (lane 3). However, the addition of
apigenin did not completely inhibit the effects of G-17 on b-catenin (lanes
2–6), suggesting that G-17 utilises multiple pathways in modulating this
important protein, including its positive regulator, protein kinase CK2.
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nevertheless possible that the increase in cyclin D1 may have
occurred independently of b-catenin-dependent transcription.
Along these lines, gastrin has been previously shown to stimulate
the expression of c-myc, another target of b-catenin, in intestinal
epithelial cells (IEC-6) (Wang et al, 1995). Although we did not
examine c-myc levels in this study, it is certainly possible that
gastrin may involve not only c-myc and cyclin D1, but also
multiple b-catenin target genes and pathways in exerting its
growth potential, whether directly or indirectly. Another possibi-
lity is simply the fact that every immortal cell line possesses
slightly different characteristics that produce disparate results. For
example, unlike AGS-B cells (Song et al, 2003b), in AGS-E cells, a
related human gastric adenocarcinoma cell line overexpressing the
gastrin receptor, G-17 induction of cyclin D1 transcription was
mediated through both b-catenin and CREB pathways (Pradeep
et al, 2004).
In conclusion, the results of the present studies demonstrate for
the first time that gastrin enhances b-catenin protein by
prolonging its half-life. Furthermore, these studies support our
hypothesis that a positive feedback mechanism exists between
gastrin and b-catenin. Although further studies will be required to
elucidate fully the mechanisms governing gastrin-induced cellular
proliferation, our results suggest that through aberrant over-
expression of b-catenin, malignant cells appear to amplify various
signals via positive feedback between molecules as a means for
potentiating tumorigenesis and proliferation.
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